L-Carnitine

L-Carnitine's primary mechanism is its role in the carnitine shuttle system, which transports long-chain fatty acids (C14–C20) across the inner mitochondrial membrane for beta-oxidation and subsequent ATP generation. Carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane converts acyl-CoA to acylcarnitine, which is then transported by carnitine-acylcarnitine translocase (CACT) into the mitochondrial matrix, where CPT-II regenerates acyl-CoA for beta-oxidation. Beyond fatty acid transport, L-carnitine buffers the acyl-CoA/CoA ratio, maintaining mitochondrial metabolic flexibility and preventing toxic accumulation of acyl-CoA intermediates. In cardiovascular tissues, L-carnitine (particularly propionyl-L-carnitine) supports cardiac energy metabolism during ischemia by maintaining ATP production and reducing lactate accumulation. L-Carnitine also modulates gene expression through its effects on peroxisome proliferator-activated receptors (PPARs) and supports antioxidant defense by reducing oxidative stress markers. For male fertility, L-carnitine concentrations in the epididymis are exceptionally high (2000× plasma levels), where it provides energy for sperm maturation and motility. A meta-analysis by DiNicolantonio et al. (2013) found significant cardiovascular mortality reduction with L-carnitine supplementation post-myocardial infarction.

L-Carnitine has been extensively studied across cardiovascular, metabolic, and reproductive health domains. DiNicolantonio et al. (2013) published a seminal meta-analysis in Mayo Clinic Proceedings examining 13 controlled trials (n=3,629) and found that L-carnitine supplementation in patients with acute myocardial infarction was associated with a 27% reduction in all-cause mortality, a 65% reduction in ventricular arrhythmias, and a 40% reduction in angina symptoms. Flanagan et al. (2010) provided a comprehensive review of carnitine's roles across disease states, including carnitine deficiency syndromes, cardiovascular disease, type 2 diabetes, renal disease, and male infertility. For weight management, Pooyandjoo et al. (2016) conducted a systematic review and meta-analysis finding that L-carnitine supplementation resulted in a statistically significant average weight loss of 1.33 kg compared to placebo, though clinical significance was modest. Balercia et al. (2004) reviewed L-carnitine's established role in male fertility, demonstrating improvements in sperm motility, morphology, and concentration. The TMAO (trimethylamine-N-oxide) concern was raised by Koeth et al. (2013), showing that gut microbiota convert carnitine to TMAO, a compound associated with cardiovascular risk; however, subsequent research suggests this effect is most relevant with chronic high-dose supplementation and may be mitigated by a healthy gut microbiome.

L-carnitine tartrate, propionyl-L-carnitine

Oral bioavailability of L-carnitine from supplements is approximately 14–18%, compared to 54–87% from food sources. Absorption decreases at higher doses; doses above 2 g result in diminishing returns. Peak plasma levels occur 2–4 hours after oral ingestion. The tartrate form may have somewhat superior absorption. Chronic supplementation increases tissue carnitine stores over weeks.

• Red meat (beef, lamb — richest dietary source)
• Pork
• Chicken and poultry
• Fish (cod, haddock)
• Dairy products (milk, cheese)
• Tempeh (modest plant source)
• Avocado (small amounts)